ImmuCell Full Year 2023 Earnings: US$0.74 loss per share (vs US$0.32 loss in FY 2022)

ImmuCell (NASDAQ:ICCC) Full Year 2023 Results

Key Financial Results

• Revenue: US$17.5m (down 5.9% from FY 2022).
• Net loss: US$5.78m (loss widened by 132% from FY 2022).
• US$0.74 loss per share (further deteriorated from US$0.32 loss in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

ImmuCell shares are up 1.5% from a week ago.

Risk Analysis

It is worth noting though that we have found 3 warning signs for ImmuCell (2 are significant!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.